Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Silexion Therapeutics ( (SLXN) ) is now available.
On September 2, 2025, Silexion Therapeutics announced an updated corporate presentation for the H.C. Wainwright Global Investment Conference, highlighting their advancements in oncogene silencing therapies. The company completed a Phase 2 clinical trial for its first-generation siRNA product, showing a significant improvement in survival for pancreatic cancer patients. They are now focusing on a second-generation product, SIL204, which has shown promising preclinical results and is set for Phase 2/3 trials in 2026. This development positions Silexion as a leader in KRAS-driven cancer therapies, with strong intellectual property protection and a strategic plan for late-stage clinical development.
The most recent analyst rating on (SLXN) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics Corp operates in the biotechnology industry, focusing on developing novel RNA interference (RNAi) therapeutics specifically targeting oncogenes. The company aims to address cancers driven by KRAS mutations, such as pancreatic, colorectal, and lung cancers, by silencing the expression of these oncogenes at the gene level, offering a potentially safer and more durable treatment approach.
Average Trading Volume: 70,764
Technical Sentiment Signal: Sell
Current Market Cap: $5.36M
See more insights into SLXN stock on TipRanks’ Stock Analysis page.